Vec-643

: Two VEC‑SBC development kits (dual‑core), CAN‑Storm traffic generator, NVH data acquisition kit, HIL test bench (dSPACE).

VEC-643 Classification: Investigational Small Molecule Profile: VEC-643 is a novel, orally bioavailable compound currently in Phase II clinical trials. It functions as a highly selective inhibitor targeting specific pathway receptors associated with treatment-resistant conditions. Preclinical data indicates that VEC-643 demonstrates superior blood-brain barrier penetration compared to standard therapies, with a favorable safety and tolerability profile. If approved, VEC-643 has the potential to establish a new standard of care for patients with limited current options. VEC-643